(Q51247242)

2 April 2018

title

Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod. (English)

1 reference

2 April 2018

0 references

8

Ralf Gold

1 reference

2 April 2018

Björn Tackenberg

4

object named as

Björn Tackenberg

1 reference

2 April 2018

author name string

Robert Hoepner

1

1 reference

2 April 2018

Joachim Havla

2

1 reference

2 April 2018

Christian Eienbröker

3

1 reference

2 April 2018

Kerstin Hellwig

5

1 reference

2 April 2018

Ingrid Meinl

6

1 reference

2 April 2018

Reinhard Hohlfeld

7

1 reference

2 April 2018

Tania Kümpfel

9

1 reference

2 April 2018

Ingo Kleiter

10

1 reference

2 April 2018

publication date

19 May 2014

1 reference

2 April 2018

Multiple Sclerosis Journal

published in

1 reference

2 April 2018

volume

20

1 reference

2 April 2018

issue

13

1 reference

2 April 2018

page(s)

1714-1720

1 reference

2 April 2018

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458514533398

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514533398

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514533398

Anti-JC virus antibodies: implications for PML risk stratification

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514533398

Bridging, switching or drug holidays - how to treat a patient who stops natalizumab?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514533398

Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514533398

De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514533398

Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514533398

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514533398

Evidence for a two-stage disability progression in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514533398

The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514533398

Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514533398

21 January 2018

Identifiers

DOI

10.1177/1352458514533398

1 reference

2 April 2018

1 reference

2 April 2018